Teva’s $40.5 billion acquisition of Allergan’s generics business, formerly known as Actavis, has gone ahead as planned – and the generics mega-merger is set to impact the UK. In order to ...

Not content with buying up a big chunk of the world’s generics market with its $40.5 billion merger with Actavis, Teva is muscling in on biosimilars with a deal with South Korea’s Celltrion.

Teva Pharmaceutical (NYSE ... the company's decision to rely heavily on U.S. generics via its $41B buyout of Actavis Generics in 2016. "Upon further reflection and dialogue with management ...